Peregrine Pharmaceuticals Announces Grant of New Patent for Vascular Targeting Agents

Peregrine Pharmaceuticals Provides Update on Status of Cotara Phase III and Schedules Quarterly Conference Call

Avid Bioservices to Present At Biologics Manufacturing Conference

Innovative Administration of Peregrine Pharmaceuticals' Radiolabeled TNT Successfully Treats Inoperable Lung Cancer

Peregrine Pharmaceuticals Announces U.S. Patent Granted for New Cancer Treatment

Patent for Peregrine Pharmaceuticals' Vasopermeation Enhancement Technology Issued

New Class of Anti-Cancer Agents Highlighted At First International Conference On Vascular Targeting

Peregrine's Vascular Targeting Agent Platform Selectively Destroys Blood Supply to Cancer Tumors in an Animal Model

Peregrine Pharmaceuticals Presents Vascular Targeting Agent Technology At BIO 2002

Peregrine Pharmaceuticals Presents Data On Vasopermeation Enhancement Agent Technology At American Society of Clinical Oncology Annual Meeting